Kromek Group PLC - Kromek awarded new DARPA bio-surveillance contract
("Kromek" or the "Group")
Kromek awarded up to
Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, is pleased to announce that it has been awarded an extension to its contract by the
Under the terms of the new contract, Kromek has been awarded up to
The miniaturised system will be capable of detecting viruses and bacteria and is intended to be located on vehicles to detect the presence of a pathogenic threat. The small, unmanned system that will run all day will also be capable of being used in high footfall areas, such as hospitals and airports.
"As the system can be vehicle mounted or placed in high footfall areas such as hospitals and airports, the location where the sample is collected can be mapped to a GPS position. The transfer of data to a central server allows a picture of pathogen levels across a city to be built up enabling decision makers to react rapidly to any evolving pathogenic threat."
This announcement contains inside information.
For further information, please contact:
| || |
+44 (0)1740 626 060
Cenkos Securities plc (Nominated Adviser and Broker)
+44 (0)20 7397 8900
| || |
+44 (0)20 7618 9100
The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.
The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").
The Group has operations in the
Currently, the Group has over one hundred full-time employees across its global operations. Further information on
This information is provided by RNS, the news service of the
Quick facts: Kromek Group PLC
Market Cap: £44.29 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE